Evaluation of a 7-day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylation

Journal of Clinical Oncology

Volumn 23, Issue 17, 2005, Pages 3897-3905

  Samlowski, Wolfram E ^a   Leachman, Sancy A ^a   Wade, Mark ^a   Cassidy, Pamela ^a   Porter Gill, Patricia ^a   Busby, Leslie ^a   Wheeler, Richard ^a   Boucher, Kenneth ^a   Fitzpatrick, Frank ^a   Jones, David A ^a   Karpf, Adam R ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GENOMIC DNA; MELANOMA ANTIGEN 1; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA METHYLATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASM; PATHOLOGY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PROMOTER REGIONS (GENETICS);

EID: 21244449980     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.118     Document Type: Article

References (35)

1. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428, 2002
2. Bender CM, Zingg JM, Jones PA: DNA methylation as a target for drug design. Pharm Res 15:175-187, 1998
3. Karpf AR, Jones DA: Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21:5496-5503, 2002
4. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93, 1980
5. Momparler RL: Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmacol Ther 30:287-299, 1985
6. Juttermann R, Li E, Jaenisch R: Toxicity of 5-aza-2′- deoxycytidinetomammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 91:11797-11801, 1994
7. Ferguson AT, Vertino PM, Spitzner JR, et al: Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2′ deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem 272:32260-32266, 1997
8. Yoshiura K, Kanai Y, Ochiai A, et al: Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A 92:7416-7419, 1995
9. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95:6870-6875, 1998
10. Myohanen SK, Baylin SB, Herman JG: Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res 58:591-593, 1998
11. Bender CM, Pao MM, Jones PA: Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58:95-101, 1998
12. Koshy M, Dorn L, Bressler L, et al: 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96:2379-2384, 2000
13. DeSimone J, Koshy M, Dorn L, et al: Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99:3905-3908, 2002
14. Silverman LR: Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 6:8-14, 2001 (5 suppl)
15. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440, 2002
16. Kantarjian HM: Treatment of myelodysplastic syndrome: Questions raised by the azacitidine experience. J Clin Oncol 20:2415-2416, 2002
17. Wijermans P, Lubbert M, Verhoef G, et al: Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962, 2000
18. Lubbert M, Wijermans P, Kunzmann R, et al: Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′- deoxycytidine. BrJ Haematol 114:349-357, 2001
19. Daskalakis M, Nguyen TT, Nguyen C, et al: Demethylation of a hypermethylated P15/ INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-2964, 2002
20. Sacchi S, Kantarjian HM, O'Brien S, et al: Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86:2632-2641, 1999
21. Issa JP, Garcia-Manero G, Giles FJ, et al: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640, 2004
22. Bovenzi V, Le NL, Cote S, et al: DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine. Anticancer Drugs 10: 471-476, 1999
23. Pohlmann P, DiLeone LP, Cancella AI, et al: Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 25:496-501, 2002
24. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
25. Wetherill GB: Serial estimation of quantal response curves. J Royal Stat Soc Series B 25: 1-48, 1963
26. De Smet C, Lurquin C, Lethe B, et al: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19:7327-7335, 1999
27. De Smet C, De Backer O, Faraoni I, et al: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation, Proc Natl Acad Sci USA 93:7149-7153, 1996
28. Gehrke CW, McCune RA, Gama-Sosa MA, et al: Quantitative reversed-phase high-performance liquid chromatography of major and modified nucleosides in DNA. J Chromatogr 301:199-219, 1984
29. Esteller M, Corn PG, Baylin SB, et al: A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229, 2001
30. Sigalotti L, Altomonte M, Colizzi F, et al: 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: A multimechanism therapeutic approach? Blood 101:4644-4646, 2003
31. Athens JW: Disorders of neutrophil proliferation and circulations: A pathophysiological view. Clin Haematol 4:553-566, 1975
32. Chan AT, Tao Q, Robertson KD, et al: Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 22:1373-1381, 2004
33. Song L, James SR, Kazim L, et al: Specific method for determinational genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectroscopy. Anal Chem 77:504-510, 2005
34. Strathdee G, MacKean MJ, Illand M, et al: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18:2335-2341, 1999
35. Karpf AR, Peterson PW, Rawlins JT, et al: Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci U S A 96:14007-14012, 1999